Fri, 21st Jun 2019 15:26
LONDON (Alliance News) - Specialist medical technology company ANGLE PLC said Tuesday that it has taken steps to strengthen its intellectual property covering its Parsortix system. The company has filed claims covering new applications for the Parsortix system, including harvesting blood ce
Read moreLONDON (Alliance News) - ANGLE PLC said Monday it has made a submission to the United States Food and Drug Administration for the authorisation of the sale of its Parsortix cell separation system as an in vitro diagnostic device in the United States. The specialist meditech firm has applied
Read moreLONDON (Alliance News) - Shares in ANGLE PLC rose 6.7% Monday after it saw positive results using its Parsortix system to analyse Circulating Tumour Cells in the blood of metastatic liver cancer patients. The test, undertaken by Hari Nageswaran at the University of Surrey's Oncology departm
Read moreLONDON (Alliance News) - The UK's inflation rate has fallen below the Bank of England's 2% target for the first time in more than four years Tuesday, a decrease that will support governor Mark Carney's recent prediction that the bank's interest rate won't rise for some time to come.
Read more
LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Tuesday. ------- FTSE 100 - WINNERS BHP Billiton, up 1.2%. The Anglo-Australian mining giant has reported an 83% increase in profit for the first half of fiscal
Read moreLONDON (Alliance News) - Shares in ANGLE PLC were on the rise Tuesday morning, after the specialist med-tech company said it will launch its Parsortix non-invasive cancer diagnostic system at a science and medical researcher conference in Berlin on Wednesday. ANGLE's pretax loss widened in
Read moreLONDON (Alliance News) - ANGLE PLC said Thursday that it was focused on establishing widespread market adoption for its Parsortix cell separation system following marketing authorisation in Europe, as its pretax loss widened in the half-year ended October 31. Parsortix is a cell separation
Read moreLONDON (Alliance News) - UK shares have opened lower Thursday, following the decision of the US Federal Reserve to continue tapering its asset purchases.
A large number of UK company reports at the open have seen a positive statement from BSkyB, up 2.4% at the open,
Medical diagnostic device maker Angle has won European approval for a system used in the diagnosis and treatment of cancer patients. Angle said regulators had authorized its Parsortix cell separation system for use as an in-vitro diagnostic device in the EU. The system uses blood analysis to diagn
Read moreSpecialist medtech company ANGLE has raised 6.2m pounds after realising its investment in graphics technology developer Geomerics, which it sold to ARM Holdings. The group said the additional financial resources will be used within its Parsortix non-invasive cancer diagnostics business, enabling i
Read moreShares in Angle, a specialist medtech company, leapt 20 per cent on Monday after the group said it has extended the operational capability of its Parsortix non-invasive cancer diagnostic product by automating its cell harvesting function. Harvesting is where captured tumour cells are recovered from
Read moreAngle, an AIM-listed specialist medtech company, has initiated the launch of its Parsortix non-invasive cancer diagnostic product for the research market. The product is based on taking a blood test, and the system either counts circulating tumour cells (CTCs) in the blood or captures and recovers
Read more